nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CYP3A4—Fingolimod—multiple sclerosis	0.11	0.246	CbGbCtD
Solifenacin—CYP3A4—Methylprednisolone—multiple sclerosis	0.0706	0.158	CbGbCtD
Solifenacin—CYP3A4—Triamcinolone—multiple sclerosis	0.0535	0.12	CbGbCtD
Solifenacin—CYP3A4—Mitoxantrone—multiple sclerosis	0.0515	0.116	CbGbCtD
Solifenacin—CYP3A4—Betamethasone—multiple sclerosis	0.0459	0.103	CbGbCtD
Solifenacin—CYP3A4—Prednisolone—multiple sclerosis	0.0453	0.102	CbGbCtD
Solifenacin—CYP3A4—Prednisone—multiple sclerosis	0.0428	0.096	CbGbCtD
Solifenacin—CYP3A4—Dexamethasone—multiple sclerosis	0.0267	0.0599	CbGbCtD
Solifenacin—Benazepril—SLC15A2—multiple sclerosis	0.013	1	CrCbGaD
Solifenacin—Urticaria—Cladribine—multiple sclerosis	0.00134	0.00308	CcSEcCtD
Solifenacin—Abdominal pain—Cladribine—multiple sclerosis	0.00133	0.00307	CcSEcCtD
Solifenacin—Skin disorder—Azathioprine—multiple sclerosis	0.00133	0.00306	CcSEcCtD
Solifenacin—Dysgeusia—Mitoxantrone—multiple sclerosis	0.00133	0.00306	CcSEcCtD
Solifenacin—Infestation NOS—Methylprednisolone—multiple sclerosis	0.00131	0.00301	CcSEcCtD
Solifenacin—Infestation—Methylprednisolone—multiple sclerosis	0.00131	0.00301	CcSEcCtD
Solifenacin—Vision blurred—Mitoxantrone—multiple sclerosis	0.00128	0.00295	CcSEcCtD
Solifenacin—Hypersensitivity—Cladribine—multiple sclerosis	0.00124	0.00286	CcSEcCtD
Solifenacin—Dry skin—Prednisone—multiple sclerosis	0.00123	0.00284	CcSEcCtD
Solifenacin—Asthenia—Cladribine—multiple sclerosis	0.00121	0.00278	CcSEcCtD
Solifenacin—Pruritus—Cladribine—multiple sclerosis	0.00119	0.00275	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Methotrexate—multiple sclerosis	0.00119	0.00274	CcSEcCtD
Solifenacin—Muscular weakness—Prednisone—multiple sclerosis	0.00119	0.00273	CcSEcCtD
Solifenacin—Cough—Mitoxantrone—multiple sclerosis	0.00119	0.00273	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00118	0.00272	CcSEcCtD
Solifenacin—Hypertension—Mitoxantrone—multiple sclerosis	0.00117	0.0027	CcSEcCtD
Solifenacin—Hallucination—Methylprednisolone—multiple sclerosis	0.00117	0.00269	CcSEcCtD
Solifenacin—Pharyngitis—Triamcinolone—multiple sclerosis	0.00117	0.00269	CcSEcCtD
Solifenacin—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.00116	0.00266	CcSEcCtD
Solifenacin—Feeling abnormal—Azathioprine—multiple sclerosis	0.00113	0.0026	CcSEcCtD
Solifenacin—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.00112	0.00258	CcSEcCtD
Solifenacin—Confusional state—Mitoxantrone—multiple sclerosis	0.00112	0.00257	CcSEcCtD
Solifenacin—Dizziness—Cladribine—multiple sclerosis	0.00112	0.00257	CcSEcCtD
Solifenacin—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.00111	0.00255	CcSEcCtD
Solifenacin—Infection—Mitoxantrone—multiple sclerosis	0.0011	0.00253	CcSEcCtD
Solifenacin—Eye disorder—Methylprednisolone—multiple sclerosis	0.0011	0.00253	CcSEcCtD
Solifenacin—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.00109	0.00251	CcSEcCtD
Solifenacin—Abdominal pain—Azathioprine—multiple sclerosis	0.00108	0.00249	CcSEcCtD
Solifenacin—Tachycardia—Mitoxantrone—multiple sclerosis	0.00108	0.00249	CcSEcCtD
Solifenacin—Skin disorder—Mitoxantrone—multiple sclerosis	0.00108	0.00248	CcSEcCtD
Solifenacin—Vomiting—Cladribine—multiple sclerosis	0.00107	0.00247	CcSEcCtD
Solifenacin—Angiopathy—Methylprednisolone—multiple sclerosis	0.00107	0.00245	CcSEcCtD
Solifenacin—Rash—Cladribine—multiple sclerosis	0.00106	0.00245	CcSEcCtD
Solifenacin—Hallucination—Betamethasone—multiple sclerosis	0.00106	0.00245	CcSEcCtD
Solifenacin—Hallucination—Dexamethasone—multiple sclerosis	0.00106	0.00245	CcSEcCtD
Solifenacin—Dermatitis—Cladribine—multiple sclerosis	0.00106	0.00244	CcSEcCtD
Solifenacin—Immune system disorder—Methylprednisolone—multiple sclerosis	0.00106	0.00244	CcSEcCtD
Solifenacin—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.00106	0.00244	CcSEcCtD
Solifenacin—Headache—Cladribine—multiple sclerosis	0.00106	0.00243	CcSEcCtD
Solifenacin—Vision blurred—Prednisolone—multiple sclerosis	0.00105	0.00242	CcSEcCtD
Solifenacin—Liver function test abnormal—Methotrexate—multiple sclerosis	0.00104	0.00239	CcSEcCtD
Solifenacin—Depression—Prednisone—multiple sclerosis	0.00103	0.00238	CcSEcCtD
Solifenacin—Mental disorder—Methylprednisolone—multiple sclerosis	0.00103	0.00237	CcSEcCtD
Solifenacin—Malnutrition—Methylprednisolone—multiple sclerosis	0.00102	0.00235	CcSEcCtD
Solifenacin—Angioedema—Prednisolone—multiple sclerosis	0.00102	0.00234	CcSEcCtD
Solifenacin—Hypersensitivity—Azathioprine—multiple sclerosis	0.00101	0.00232	CcSEcCtD
Solifenacin—Dysgeusia—Triamcinolone—multiple sclerosis	0.001	0.00231	CcSEcCtD
Solifenacin—Nausea—Cladribine—multiple sclerosis	0.001	0.0023	CcSEcCtD
Solifenacin—Eye disorder—Betamethasone—multiple sclerosis	0.000999	0.0023	CcSEcCtD
Solifenacin—Eye disorder—Dexamethasone—multiple sclerosis	0.000999	0.0023	CcSEcCtD
Solifenacin—Somnolence—Mitoxantrone—multiple sclerosis	0.000986	0.00227	CcSEcCtD
Solifenacin—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000977	0.00225	CcSEcCtD
Solifenacin—Angiopathy—Betamethasone—multiple sclerosis	0.00097	0.00223	CcSEcCtD
Solifenacin—Angiopathy—Dexamethasone—multiple sclerosis	0.00097	0.00223	CcSEcCtD
Solifenacin—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000964	0.00222	CcSEcCtD
Solifenacin—Hypertension—Prednisolone—multiple sclerosis	0.000963	0.00221	CcSEcCtD
Solifenacin—Fatigue—Mitoxantrone—multiple sclerosis	0.000957	0.0022	CcSEcCtD
Solifenacin—Constipation—Mitoxantrone—multiple sclerosis	0.000949	0.00218	CcSEcCtD
Solifenacin—Angioedema—Triamcinolone—multiple sclerosis	0.000937	0.00215	CcSEcCtD
Solifenacin—Angioedema—Methylprednisolone—multiple sclerosis	0.000935	0.00215	CcSEcCtD
Solifenacin—Hallucination—Prednisone—multiple sclerosis	0.000926	0.00213	CcSEcCtD
Solifenacin—Connective tissue disorder—Prednisone—multiple sclerosis	0.000915	0.0021	CcSEcCtD
Solifenacin—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000914	0.0021	CcSEcCtD
Solifenacin—Anaphylactic shock—Prednisolone—multiple sclerosis	0.00091	0.00209	CcSEcCtD
Solifenacin—Dysuria—Methotrexate—multiple sclerosis	0.000909	0.00209	CcSEcCtD
Solifenacin—Dizziness—Azathioprine—multiple sclerosis	0.000908	0.00209	CcSEcCtD
Solifenacin—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000907	0.00209	CcSEcCtD
Solifenacin—Cough—Triamcinolone—multiple sclerosis	0.000895	0.00206	CcSEcCtD
Solifenacin—Tachycardia—Prednisolone—multiple sclerosis	0.000888	0.00204	CcSEcCtD
Solifenacin—Hypertension—Triamcinolone—multiple sclerosis	0.000885	0.00204	CcSEcCtD
Solifenacin—Hypertension—Methylprednisolone—multiple sclerosis	0.000884	0.00203	CcSEcCtD
Solifenacin—Urticaria—Mitoxantrone—multiple sclerosis	0.000881	0.00203	CcSEcCtD
Solifenacin—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000877	0.00202	CcSEcCtD
Solifenacin—Vomiting—Azathioprine—multiple sclerosis	0.000873	0.00201	CcSEcCtD
Solifenacin—Eye disorder—Prednisone—multiple sclerosis	0.00087	0.002	CcSEcCtD
Solifenacin—Infestation NOS—Methotrexate—multiple sclerosis	0.000867	0.00199	CcSEcCtD
Solifenacin—Infestation—Methotrexate—multiple sclerosis	0.000867	0.00199	CcSEcCtD
Solifenacin—Rash—Azathioprine—multiple sclerosis	0.000865	0.00199	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000865	0.00199	CcSEcCtD
Solifenacin—Dermatitis—Azathioprine—multiple sclerosis	0.000865	0.00199	CcSEcCtD
Solifenacin—Depression—Methotrexate—multiple sclerosis	0.000864	0.00199	CcSEcCtD
Solifenacin—Headache—Azathioprine—multiple sclerosis	0.00086	0.00198	CcSEcCtD
Solifenacin—Dry mouth—Triamcinolone—multiple sclerosis	0.000854	0.00196	CcSEcCtD
Solifenacin—Renal failure—Methotrexate—multiple sclerosis	0.000852	0.00196	CcSEcCtD
Solifenacin—Angioedema—Dexamethasone—multiple sclerosis	0.00085	0.00195	CcSEcCtD
Solifenacin—Angioedema—Betamethasone—multiple sclerosis	0.00085	0.00195	CcSEcCtD
Solifenacin—Angiopathy—Prednisone—multiple sclerosis	0.000845	0.00194	CcSEcCtD
Solifenacin—Confusional state—Methylprednisolone—multiple sclerosis	0.000842	0.00194	CcSEcCtD
Solifenacin—Immune system disorder—Prednisone—multiple sclerosis	0.000841	0.00193	CcSEcCtD
Solifenacin—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000837	0.00192	CcSEcCtD
Solifenacin—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000835	0.00192	CcSEcCtD
Solifenacin—Infection—Triamcinolone—multiple sclerosis	0.000832	0.00191	CcSEcCtD
Solifenacin—Infection—Methylprednisolone—multiple sclerosis	0.00083	0.00191	CcSEcCtD
Solifenacin—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.00082	0.00188	CcSEcCtD
Solifenacin—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000819	0.00188	CcSEcCtD
Solifenacin—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000817	0.00188	CcSEcCtD
Solifenacin—Tachycardia—Triamcinolone—multiple sclerosis	0.000817	0.00188	CcSEcCtD
Solifenacin—Mental disorder—Prednisone—multiple sclerosis	0.000816	0.00188	CcSEcCtD
Solifenacin—Nausea—Azathioprine—multiple sclerosis	0.000815	0.00187	CcSEcCtD
Solifenacin—Tachycardia—Methylprednisolone—multiple sclerosis	0.000815	0.00187	CcSEcCtD
Solifenacin—Skin disorder—Methylprednisolone—multiple sclerosis	0.000811	0.00186	CcSEcCtD
Solifenacin—Malnutrition—Prednisone—multiple sclerosis	0.00081	0.00186	CcSEcCtD
Solifenacin—Hypertension—Dexamethasone—multiple sclerosis	0.000803	0.00185	CcSEcCtD
Solifenacin—Hypertension—Betamethasone—multiple sclerosis	0.000803	0.00185	CcSEcCtD
Solifenacin—Asthenia—Mitoxantrone—multiple sclerosis	0.000796	0.00183	CcSEcCtD
Solifenacin—Pharyngitis—Methotrexate—multiple sclerosis	0.000772	0.00178	CcSEcCtD
Solifenacin—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000768	0.00177	CcSEcCtD
Solifenacin—Vision blurred—Prednisone—multiple sclerosis	0.000764	0.00176	CcSEcCtD
Solifenacin—Urethral disorder—Methotrexate—multiple sclerosis	0.000763	0.00175	CcSEcCtD
Solifenacin—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000759	0.00175	CcSEcCtD
Solifenacin—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000759	0.00175	CcSEcCtD
Solifenacin—Infection—Betamethasone—multiple sclerosis	0.000755	0.00173	CcSEcCtD
Solifenacin—Infection—Dexamethasone—multiple sclerosis	0.000755	0.00173	CcSEcCtD
Solifenacin—Feeling abnormal—Prednisolone—multiple sclerosis	0.00075	0.00172	CcSEcCtD
Solifenacin—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000745	0.00171	CcSEcCtD
Solifenacin—Nervous system disorder—Betamethasone—multiple sclerosis	0.000745	0.00171	CcSEcCtD
Solifenacin—Tachycardia—Dexamethasone—multiple sclerosis	0.000741	0.0017	CcSEcCtD
Solifenacin—Tachycardia—Betamethasone—multiple sclerosis	0.000741	0.0017	CcSEcCtD
Solifenacin—Angioedema—Prednisone—multiple sclerosis	0.000741	0.0017	CcSEcCtD
Solifenacin—Dyspepsia—Triamcinolone—multiple sclerosis	0.000737	0.00169	CcSEcCtD
Solifenacin—Erythema multiforme—Methotrexate—multiple sclerosis	0.000736	0.00169	CcSEcCtD
Solifenacin—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000735	0.00169	CcSEcCtD
Solifenacin—Eye disorder—Methotrexate—multiple sclerosis	0.000727	0.00167	CcSEcCtD
Solifenacin—Urticaria—Prednisolone—multiple sclerosis	0.000723	0.00166	CcSEcCtD
Solifenacin—Cardiac disorder—Methotrexate—multiple sclerosis	0.000722	0.00166	CcSEcCtD
Solifenacin—Fatigue—Triamcinolone—multiple sclerosis	0.000722	0.00166	CcSEcCtD
Solifenacin—Fatigue—Methylprednisolone—multiple sclerosis	0.00072	0.00166	CcSEcCtD
Solifenacin—Angiopathy—Methotrexate—multiple sclerosis	0.000706	0.00162	CcSEcCtD
Solifenacin—Vomiting—Mitoxantrone—multiple sclerosis	0.000705	0.00162	CcSEcCtD
Solifenacin—Immune system disorder—Methotrexate—multiple sclerosis	0.000703	0.00162	CcSEcCtD
Solifenacin—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000701	0.00161	CcSEcCtD
Solifenacin—Hypertension—Prednisone—multiple sclerosis	0.0007	0.00161	CcSEcCtD
Solifenacin—Rash—Mitoxantrone—multiple sclerosis	0.0007	0.00161	CcSEcCtD
Solifenacin—Dermatitis—Mitoxantrone—multiple sclerosis	0.000699	0.00161	CcSEcCtD
Solifenacin—Headache—Mitoxantrone—multiple sclerosis	0.000695	0.0016	CcSEcCtD
Solifenacin—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00069	0.00159	CcSEcCtD
Solifenacin—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000688	0.00158	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000685	0.00158	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000683	0.00157	CcSEcCtD
Solifenacin—Mental disorder—Methotrexate—multiple sclerosis	0.000682	0.00157	CcSEcCtD
Solifenacin—Malnutrition—Methotrexate—multiple sclerosis	0.000677	0.00156	CcSEcCtD
Solifenacin—Hypersensitivity—Prednisolone—multiple sclerosis	0.000671	0.00154	CcSEcCtD
Solifenacin—Dyspepsia—Dexamethasone—multiple sclerosis	0.000669	0.00154	CcSEcCtD
Solifenacin—Dyspepsia—Betamethasone—multiple sclerosis	0.000669	0.00154	CcSEcCtD
Solifenacin—Urticaria—Triamcinolone—multiple sclerosis	0.000665	0.00153	CcSEcCtD
Solifenacin—Urticaria—Methylprednisolone—multiple sclerosis	0.000663	0.00153	CcSEcCtD
Solifenacin—Dysgeusia—Methotrexate—multiple sclerosis	0.000663	0.00152	CcSEcCtD
Solifenacin—Anaphylactic shock—Prednisone—multiple sclerosis	0.000661	0.00152	CcSEcCtD
Solifenacin—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00066	0.00152	CcSEcCtD
Solifenacin—Decreased appetite—Betamethasone—multiple sclerosis	0.00066	0.00152	CcSEcCtD
Solifenacin—Decreased appetite—Dexamethasone—multiple sclerosis	0.00066	0.00152	CcSEcCtD
Solifenacin—Nausea—Mitoxantrone—multiple sclerosis	0.000659	0.00152	CcSEcCtD
Solifenacin—Infection—Prednisone—multiple sclerosis	0.000657	0.00151	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000656	0.00151	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000656	0.00151	CcSEcCtD
Solifenacin—Fatigue—Dexamethasone—multiple sclerosis	0.000655	0.00151	CcSEcCtD
Solifenacin—Fatigue—Betamethasone—multiple sclerosis	0.000655	0.00151	CcSEcCtD
Solifenacin—Nervous system disorder—Prednisone—multiple sclerosis	0.000649	0.00149	CcSEcCtD
Solifenacin—Tachycardia—Prednisone—multiple sclerosis	0.000646	0.00148	CcSEcCtD
Solifenacin—Skin disorder—Prednisone—multiple sclerosis	0.000642	0.00148	CcSEcCtD
Solifenacin—Vision blurred—Methotrexate—multiple sclerosis	0.000638	0.00147	CcSEcCtD
Solifenacin—Feeling abnormal—Betamethasone—multiple sclerosis	0.000626	0.00144	CcSEcCtD
Solifenacin—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000626	0.00144	CcSEcCtD
Solifenacin—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000621	0.00143	CcSEcCtD
Solifenacin—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000621	0.00143	CcSEcCtD
Solifenacin—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000617	0.00142	CcSEcCtD
Solifenacin—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000615	0.00141	CcSEcCtD
Solifenacin—Urticaria—Betamethasone—multiple sclerosis	0.000603	0.00139	CcSEcCtD
Solifenacin—Urticaria—Dexamethasone—multiple sclerosis	0.000603	0.00139	CcSEcCtD
Solifenacin—Dizziness—Prednisolone—multiple sclerosis	0.000602	0.00138	CcSEcCtD
Solifenacin—Asthenia—Triamcinolone—multiple sclerosis	0.000601	0.00138	CcSEcCtD
Solifenacin—Abdominal pain—Betamethasone—multiple sclerosis	0.0006	0.00138	CcSEcCtD
Solifenacin—Abdominal pain—Dexamethasone—multiple sclerosis	0.0006	0.00138	CcSEcCtD
Solifenacin—Asthenia—Methylprednisolone—multiple sclerosis	0.000599	0.00138	CcSEcCtD
Solifenacin—Pruritus—Triamcinolone—multiple sclerosis	0.000592	0.00136	CcSEcCtD
Solifenacin—Cough—Methotrexate—multiple sclerosis	0.000591	0.00136	CcSEcCtD
Solifenacin—Pruritus—Methylprednisolone—multiple sclerosis	0.000591	0.00136	CcSEcCtD
Solifenacin—Dyspepsia—Prednisone—multiple sclerosis	0.000582	0.00134	CcSEcCtD
Solifenacin—Decreased appetite—Prednisone—multiple sclerosis	0.000575	0.00132	CcSEcCtD
Solifenacin—Rash—Prednisolone—multiple sclerosis	0.000574	0.00132	CcSEcCtD
Solifenacin—Dermatitis—Prednisolone—multiple sclerosis	0.000573	0.00132	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000573	0.00132	CcSEcCtD
Solifenacin—Fatigue—Prednisone—multiple sclerosis	0.00057	0.00131	CcSEcCtD
Solifenacin—Headache—Prednisolone—multiple sclerosis	0.00057	0.00131	CcSEcCtD
Solifenacin—Constipation—Prednisone—multiple sclerosis	0.000566	0.0013	CcSEcCtD
Solifenacin—Confusional state—Methotrexate—multiple sclerosis	0.000557	0.00128	CcSEcCtD
Solifenacin—Dizziness—Triamcinolone—multiple sclerosis	0.000554	0.00127	CcSEcCtD
Solifenacin—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000553	0.00127	CcSEcCtD
Solifenacin—Dizziness—Methylprednisolone—multiple sclerosis	0.000552	0.00127	CcSEcCtD
Solifenacin—Infection—Methotrexate—multiple sclerosis	0.000549	0.00126	CcSEcCtD
Solifenacin—Feeling abnormal—Prednisone—multiple sclerosis	0.000545	0.00125	CcSEcCtD
Solifenacin—Asthenia—Dexamethasone—multiple sclerosis	0.000545	0.00125	CcSEcCtD
Solifenacin—Asthenia—Betamethasone—multiple sclerosis	0.000545	0.00125	CcSEcCtD
Solifenacin—Nervous system disorder—Methotrexate—multiple sclerosis	0.000542	0.00125	CcSEcCtD
Solifenacin—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000541	0.00124	CcSEcCtD
Solifenacin—Nausea—Prednisolone—multiple sclerosis	0.000541	0.00124	CcSEcCtD
Solifenacin—Pruritus—Dexamethasone—multiple sclerosis	0.000537	0.00124	CcSEcCtD
Solifenacin—Pruritus—Betamethasone—multiple sclerosis	0.000537	0.00124	CcSEcCtD
Solifenacin—Skin disorder—Methotrexate—multiple sclerosis	0.000537	0.00123	CcSEcCtD
Solifenacin—Vomiting—Triamcinolone—multiple sclerosis	0.000532	0.00122	CcSEcCtD
Solifenacin—Vomiting—Methylprednisolone—multiple sclerosis	0.000531	0.00122	CcSEcCtD
Solifenacin—Rash—Triamcinolone—multiple sclerosis	0.000528	0.00121	CcSEcCtD
Solifenacin—Dermatitis—Triamcinolone—multiple sclerosis	0.000527	0.00121	CcSEcCtD
Solifenacin—Rash—Methylprednisolone—multiple sclerosis	0.000527	0.00121	CcSEcCtD
Solifenacin—Dermatitis—Methylprednisolone—multiple sclerosis	0.000526	0.00121	CcSEcCtD
Solifenacin—Urticaria—Prednisone—multiple sclerosis	0.000525	0.00121	CcSEcCtD
Solifenacin—Headache—Triamcinolone—multiple sclerosis	0.000524	0.00121	CcSEcCtD
Solifenacin—Headache—Methylprednisolone—multiple sclerosis	0.000523	0.0012	CcSEcCtD
Solifenacin—Abdominal pain—Prednisone—multiple sclerosis	0.000523	0.0012	CcSEcCtD
Solifenacin—Dizziness—Dexamethasone—multiple sclerosis	0.000502	0.00115	CcSEcCtD
Solifenacin—Dizziness—Betamethasone—multiple sclerosis	0.000502	0.00115	CcSEcCtD
Solifenacin—Nausea—Triamcinolone—multiple sclerosis	0.000497	0.00114	CcSEcCtD
Solifenacin—Nausea—Methylprednisolone—multiple sclerosis	0.000496	0.00114	CcSEcCtD
Solifenacin—Somnolence—Methotrexate—multiple sclerosis	0.000491	0.00113	CcSEcCtD
Solifenacin—Hypersensitivity—Prednisone—multiple sclerosis	0.000487	0.00112	CcSEcCtD
Solifenacin—Dyspepsia—Methotrexate—multiple sclerosis	0.000487	0.00112	CcSEcCtD
Solifenacin—Vomiting—Betamethasone—multiple sclerosis	0.000483	0.00111	CcSEcCtD
Solifenacin—Vomiting—Dexamethasone—multiple sclerosis	0.000483	0.00111	CcSEcCtD
Solifenacin—Decreased appetite—Methotrexate—multiple sclerosis	0.000481	0.0011	CcSEcCtD
Solifenacin—Rash—Betamethasone—multiple sclerosis	0.000479	0.0011	CcSEcCtD
Solifenacin—Rash—Dexamethasone—multiple sclerosis	0.000479	0.0011	CcSEcCtD
Solifenacin—Dermatitis—Dexamethasone—multiple sclerosis	0.000478	0.0011	CcSEcCtD
Solifenacin—Dermatitis—Betamethasone—multiple sclerosis	0.000478	0.0011	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000477	0.0011	CcSEcCtD
Solifenacin—Fatigue—Methotrexate—multiple sclerosis	0.000477	0.0011	CcSEcCtD
Solifenacin—Headache—Betamethasone—multiple sclerosis	0.000476	0.00109	CcSEcCtD
Solifenacin—Headache—Dexamethasone—multiple sclerosis	0.000476	0.00109	CcSEcCtD
Solifenacin—Asthenia—Prednisone—multiple sclerosis	0.000475	0.00109	CcSEcCtD
Solifenacin—Pruritus—Prednisone—multiple sclerosis	0.000468	0.00108	CcSEcCtD
Solifenacin—Feeling abnormal—Methotrexate—multiple sclerosis	0.000456	0.00105	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000452	0.00104	CcSEcCtD
Solifenacin—Nausea—Betamethasone—multiple sclerosis	0.000451	0.00104	CcSEcCtD
Solifenacin—Nausea—Dexamethasone—multiple sclerosis	0.000451	0.00104	CcSEcCtD
Solifenacin—Urticaria—Methotrexate—multiple sclerosis	0.000439	0.00101	CcSEcCtD
Solifenacin—Dizziness—Prednisone—multiple sclerosis	0.000437	0.00101	CcSEcCtD
Solifenacin—Abdominal pain—Methotrexate—multiple sclerosis	0.000437	0.001	CcSEcCtD
Solifenacin—Vomiting—Prednisone—multiple sclerosis	0.000421	0.000967	CcSEcCtD
Solifenacin—Rash—Prednisone—multiple sclerosis	0.000417	0.000959	CcSEcCtD
Solifenacin—Dermatitis—Prednisone—multiple sclerosis	0.000417	0.000958	CcSEcCtD
Solifenacin—Headache—Prednisone—multiple sclerosis	0.000414	0.000953	CcSEcCtD
Solifenacin—Hypersensitivity—Methotrexate—multiple sclerosis	0.000407	0.000936	CcSEcCtD
Solifenacin—Asthenia—Methotrexate—multiple sclerosis	0.000397	0.000912	CcSEcCtD
Solifenacin—Nausea—Prednisone—multiple sclerosis	0.000393	0.000903	CcSEcCtD
Solifenacin—Pruritus—Methotrexate—multiple sclerosis	0.000391	0.000899	CcSEcCtD
Solifenacin—Dizziness—Methotrexate—multiple sclerosis	0.000366	0.00084	CcSEcCtD
Solifenacin—Vomiting—Methotrexate—multiple sclerosis	0.000351	0.000808	CcSEcCtD
Solifenacin—Rash—Methotrexate—multiple sclerosis	0.000349	0.000801	CcSEcCtD
Solifenacin—Dermatitis—Methotrexate—multiple sclerosis	0.000348	0.000801	CcSEcCtD
Solifenacin—Headache—Methotrexate—multiple sclerosis	0.000346	0.000796	CcSEcCtD
Solifenacin—Nausea—Methotrexate—multiple sclerosis	0.000328	0.000755	CcSEcCtD
Solifenacin—CHRM4—Signaling by GPCR—CCL5—multiple sclerosis	8.49e-05	0.000801	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RGS1—multiple sclerosis	8.46e-05	0.000798	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RGS1—multiple sclerosis	8.43e-05	0.000796	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CCR5—multiple sclerosis	8.42e-05	0.000795	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PTGER4—multiple sclerosis	8.4e-05	0.000793	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RGS1—multiple sclerosis	8.35e-05	0.000788	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—IL2RA—multiple sclerosis	8.3e-05	0.000783	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CXCR3—multiple sclerosis	8.22e-05	0.000776	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCR3—multiple sclerosis	8.2e-05	0.000774	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CNR1—multiple sclerosis	8.13e-05	0.000767	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CCL5—multiple sclerosis	8.13e-05	0.000767	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCR3—multiple sclerosis	8.12e-05	0.000766	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CNR1—multiple sclerosis	8.1e-05	0.000765	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CCR5—multiple sclerosis	8.06e-05	0.000761	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CNR1—multiple sclerosis	8.02e-05	0.000758	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—GPR65—multiple sclerosis	8.02e-05	0.000757	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCR2—multiple sclerosis	8e-05	0.000755	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—GPR65—multiple sclerosis	7.99e-05	0.000754	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCR2—multiple sclerosis	7.97e-05	0.000753	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—IL2RA—multiple sclerosis	7.94e-05	0.00075	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—GPR65—multiple sclerosis	7.91e-05	0.000747	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCR2—multiple sclerosis	7.9e-05	0.000745	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	7.87e-05	0.000743	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—POMC—multiple sclerosis	7.85e-05	0.000741	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	7.85e-05	0.000741	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—POMC—multiple sclerosis	7.82e-05	0.000739	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—POMC—multiple sclerosis	7.75e-05	0.000732	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCL3—multiple sclerosis	7.75e-05	0.000732	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—IL6—multiple sclerosis	7.72e-05	0.000729	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CCL2—multiple sclerosis	7.68e-05	0.000725	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CCL2—multiple sclerosis	7.66e-05	0.000723	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CCR5—multiple sclerosis	7.64e-05	0.000722	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CCL2—multiple sclerosis	7.58e-05	0.000716	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL2RA—multiple sclerosis	7.53e-05	0.000711	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PTGER4—multiple sclerosis	7.46e-05	0.000704	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCL3—multiple sclerosis	7.42e-05	0.000701	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CNR1—multiple sclerosis	7.38e-05	0.000697	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CNR1—multiple sclerosis	7.36e-05	0.000695	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PGR—multiple sclerosis	7.35e-05	0.000693	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCR1—multiple sclerosis	7.33e-05	0.000692	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL13—multiple sclerosis	7.33e-05	0.000692	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CCR5—multiple sclerosis	7.32e-05	0.000691	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	7.32e-05	0.000691	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCR1—multiple sclerosis	7.31e-05	0.00069	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL13—multiple sclerosis	7.31e-05	0.00069	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CXCL10—multiple sclerosis	7.3e-05	0.000689	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CNR1—multiple sclerosis	7.29e-05	0.000688	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL13—multiple sclerosis	7.24e-05	0.000683	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCR1—multiple sclerosis	7.24e-05	0.000683	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CXCL10—multiple sclerosis	7.22e-05	0.000682	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL2RA—multiple sclerosis	7.21e-05	0.000681	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCR3—multiple sclerosis	7.2e-05	0.00068	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PTGER4—multiple sclerosis	7.14e-05	0.000674	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CD28—multiple sclerosis	7.14e-05	0.000674	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PGR—multiple sclerosis	7.03e-05	0.000664	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCR2—multiple sclerosis	7.01e-05	0.000662	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SRM—multiple sclerosis	7e-05	0.000661	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCR3—multiple sclerosis	6.9e-05	0.000651	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CD28—multiple sclerosis	6.83e-05	0.000645	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCR2—multiple sclerosis	6.71e-05	0.000634	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CXCL10—multiple sclerosis	6.65e-05	0.000627	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCL10—multiple sclerosis	6.63e-05	0.000625	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—POMC—multiple sclerosis	6.58e-05	0.000621	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCL10—multiple sclerosis	6.56e-05	0.000619	CbGpPWpGaD
Solifenacin—CYP3A4—Biological oxidations—POMC—multiple sclerosis	6.49e-05	0.000612	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CNR1—multiple sclerosis	6.47e-05	0.000611	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—IL6—multiple sclerosis	6.38e-05	0.000603	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—POMC—multiple sclerosis	6.3e-05	0.000595	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CCL5—multiple sclerosis	6.3e-05	0.000595	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CCL5—multiple sclerosis	6.28e-05	0.000593	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CCL5—multiple sclerosis	6.22e-05	0.000587	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CNR1—multiple sclerosis	6.19e-05	0.000585	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	6.05e-05	0.000571	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	6.03e-05	0.000569	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—POMC—multiple sclerosis	5.97e-05	0.000564	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CCL2—multiple sclerosis	5.85e-05	0.000552	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCL10—multiple sclerosis	5.82e-05	0.00055	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCL5—multiple sclerosis	5.72e-05	0.00054	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—POMC—multiple sclerosis	5.72e-05	0.00054	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCL5—multiple sclerosis	5.7e-05	0.000538	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CCR5—multiple sclerosis	5.68e-05	0.000536	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CCR5—multiple sclerosis	5.66e-05	0.000534	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCL5—multiple sclerosis	5.65e-05	0.000533	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CCR5—multiple sclerosis	5.6e-05	0.000529	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CCL2—multiple sclerosis	5.6e-05	0.000528	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	5.59e-05	0.000528	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCL10—multiple sclerosis	5.58e-05	0.000526	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—IL2RA—multiple sclerosis	5.58e-05	0.000526	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—IL2RA—multiple sclerosis	5.52e-05	0.000521	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—BCHE—multiple sclerosis	5.49e-05	0.000518	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—TYK2—multiple sclerosis	5.31e-05	0.000501	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL3—multiple sclerosis	5.22e-05	0.000493	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL3—multiple sclerosis	5.21e-05	0.000492	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL3—multiple sclerosis	5.16e-05	0.000487	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCR5—multiple sclerosis	5.15e-05	0.000487	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCR5—multiple sclerosis	5.14e-05	0.000485	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CD86—multiple sclerosis	5.09e-05	0.000481	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCR5—multiple sclerosis	5.09e-05	0.00048	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—TYK2—multiple sclerosis	5.08e-05	0.00048	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL2RA—multiple sclerosis	5.08e-05	0.00048	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL2RA—multiple sclerosis	5.06e-05	0.000478	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PTGER4—multiple sclerosis	5.03e-05	0.000475	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL2RA—multiple sclerosis	5.01e-05	0.000473	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PTGER4—multiple sclerosis	5.01e-05	0.000473	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCL5—multiple sclerosis	5.01e-05	0.000473	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PTGER4—multiple sclerosis	4.96e-05	0.000469	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PGR—multiple sclerosis	4.95e-05	0.000468	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PGR—multiple sclerosis	4.94e-05	0.000466	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	4.93e-05	0.000465	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	4.93e-05	0.000465	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PGR—multiple sclerosis	4.89e-05	0.000462	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CD86—multiple sclerosis	4.88e-05	0.00046	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—IL2—multiple sclerosis	4.86e-05	0.000459	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCR3—multiple sclerosis	4.86e-05	0.000459	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCR3—multiple sclerosis	4.84e-05	0.000457	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CD28—multiple sclerosis	4.81e-05	0.000454	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCL5—multiple sclerosis	4.8e-05	0.000453	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CD28—multiple sclerosis	4.8e-05	0.000453	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCR3—multiple sclerosis	4.79e-05	0.000453	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CD28—multiple sclerosis	4.75e-05	0.000448	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCR2—multiple sclerosis	4.73e-05	0.000446	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCR2—multiple sclerosis	4.71e-05	0.000445	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCR2—multiple sclerosis	4.66e-05	0.00044	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—IL2—multiple sclerosis	4.66e-05	0.00044	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SPP1—multiple sclerosis	4.64e-05	0.000438	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCR5—multiple sclerosis	4.52e-05	0.000426	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GPC5—multiple sclerosis	4.51e-05	0.000426	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL2RA—multiple sclerosis	4.45e-05	0.00042	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SPP1—multiple sclerosis	4.45e-05	0.00042	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—POMC—multiple sclerosis	4.44e-05	0.000419	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—POMC—multiple sclerosis	4.42e-05	0.000417	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL2—multiple sclerosis	4.42e-05	0.000417	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—POMC—multiple sclerosis	4.38e-05	0.000413	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CNR1—multiple sclerosis	4.36e-05	0.000412	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CNR1—multiple sclerosis	4.35e-05	0.00041	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCR5—multiple sclerosis	4.32e-05	0.000408	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CNR1—multiple sclerosis	4.3e-05	0.000406	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL2RA—multiple sclerosis	4.26e-05	0.000402	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL2—multiple sclerosis	4.23e-05	0.000399	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—APOE—multiple sclerosis	4.11e-05	0.000388	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—POMC—multiple sclerosis	4.03e-05	0.00038	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—POMC—multiple sclerosis	4.02e-05	0.000379	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—POMC—multiple sclerosis	3.98e-05	0.000375	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCL2—multiple sclerosis	3.94e-05	0.000372	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—APOE—multiple sclerosis	3.93e-05	0.000371	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCL2—multiple sclerosis	3.93e-05	0.000371	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL10—multiple sclerosis	3.93e-05	0.000371	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL10—multiple sclerosis	3.91e-05	0.000369	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCL2—multiple sclerosis	3.89e-05	0.000367	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL10—multiple sclerosis	3.88e-05	0.000366	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.74e-05	0.000353	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CD80—multiple sclerosis	3.71e-05	0.000351	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—TYK2—multiple sclerosis	3.58e-05	0.000338	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—TYK2—multiple sclerosis	3.57e-05	0.000337	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CD80—multiple sclerosis	3.56e-05	0.000336	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—TYK2—multiple sclerosis	3.53e-05	0.000334	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—POMC—multiple sclerosis	3.53e-05	0.000333	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCL2—multiple sclerosis	3.45e-05	0.000326	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CD86—multiple sclerosis	3.43e-05	0.000324	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CD86—multiple sclerosis	3.42e-05	0.000323	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CD86—multiple sclerosis	3.39e-05	0.00032	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL5—multiple sclerosis	3.38e-05	0.000319	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—POMC—multiple sclerosis	3.38e-05	0.000319	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—MAPK1—multiple sclerosis	3.38e-05	0.000319	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL5—multiple sclerosis	3.37e-05	0.000318	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL5—multiple sclerosis	3.34e-05	0.000315	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCL2—multiple sclerosis	3.31e-05	0.000312	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—APOE—multiple sclerosis	3.3e-05	0.000312	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—IL2—multiple sclerosis	3.28e-05	0.00031	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—IL2—multiple sclerosis	3.27e-05	0.000309	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—IL2—multiple sclerosis	3.24e-05	0.000306	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—MAPK1—multiple sclerosis	3.24e-05	0.000305	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TYK2—multiple sclerosis	3.14e-05	0.000296	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SPP1—multiple sclerosis	3.13e-05	0.000295	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SPP1—multiple sclerosis	3.12e-05	0.000295	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SPP1—multiple sclerosis	3.09e-05	0.000292	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCR5—multiple sclerosis	3.04e-05	0.000287	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCR5—multiple sclerosis	3.04e-05	0.000287	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCR5—multiple sclerosis	3.01e-05	0.000284	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TYK2—multiple sclerosis	3e-05	0.000283	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL2RA—multiple sclerosis	3e-05	0.000283	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL2RA—multiple sclerosis	2.99e-05	0.000282	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL2—multiple sclerosis	2.98e-05	0.000281	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL2—multiple sclerosis	2.97e-05	0.00028	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL2RA—multiple sclerosis	2.96e-05	0.00028	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL2—multiple sclerosis	2.94e-05	0.000278	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—POMC—multiple sclerosis	2.84e-05	0.000268	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APOE—multiple sclerosis	2.77e-05	0.000262	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APOE—multiple sclerosis	2.76e-05	0.000261	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APOE—multiple sclerosis	2.73e-05	0.000258	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL2—multiple sclerosis	2.61e-05	0.000246	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL6—multiple sclerosis	2.6e-05	0.000245	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALB—multiple sclerosis	2.59e-05	0.000244	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CD80—multiple sclerosis	2.5e-05	0.000236	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL2—multiple sclerosis	2.5e-05	0.000236	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CD80—multiple sclerosis	2.5e-05	0.000236	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6—multiple sclerosis	2.49e-05	0.000235	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CD80—multiple sclerosis	2.47e-05	0.000233	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MMP9—multiple sclerosis	2.47e-05	0.000233	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—POMC—multiple sclerosis	2.38e-05	0.000225	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—POMC—multiple sclerosis	2.37e-05	0.000224	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MMP9—multiple sclerosis	2.36e-05	0.000223	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—POMC—multiple sclerosis	2.35e-05	0.000222	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL2—multiple sclerosis	2.33e-05	0.00022	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL2—multiple sclerosis	2.32e-05	0.000219	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL2—multiple sclerosis	2.3e-05	0.000217	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—MAPK1—multiple sclerosis	2.28e-05	0.000215	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—MAPK1—multiple sclerosis	2.27e-05	0.000214	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—MAPK1—multiple sclerosis	2.25e-05	0.000212	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—STAT3—multiple sclerosis	2.2e-05	0.000207	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—BCHE—multiple sclerosis	2.15e-05	0.000203	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TYK2—multiple sclerosis	2.11e-05	0.0002	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TYK2—multiple sclerosis	2.11e-05	0.000199	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—STAT3—multiple sclerosis	2.1e-05	0.000198	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TYK2—multiple sclerosis	2.09e-05	0.000197	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MYC—multiple sclerosis	2.04e-05	0.000193	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFB1—multiple sclerosis	2.04e-05	0.000192	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MAPK1—multiple sclerosis	2e-05	0.000188	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MYC—multiple sclerosis	1.95e-05	0.000184	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFB1—multiple sclerosis	1.95e-05	0.000184	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MAPK1—multiple sclerosis	1.91e-05	0.00018	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL2—multiple sclerosis	1.76e-05	0.000166	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL2—multiple sclerosis	1.75e-05	0.000166	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6—multiple sclerosis	1.75e-05	0.000165	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6—multiple sclerosis	1.74e-05	0.000165	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL2—multiple sclerosis	1.74e-05	0.000164	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6—multiple sclerosis	1.73e-05	0.000163	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MMP9—multiple sclerosis	1.67e-05	0.000157	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MMP9—multiple sclerosis	1.66e-05	0.000157	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MMP9—multiple sclerosis	1.64e-05	0.000155	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6—multiple sclerosis	1.53e-05	0.000145	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—STAT3—multiple sclerosis	1.48e-05	0.00014	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—STAT3—multiple sclerosis	1.48e-05	0.000139	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6—multiple sclerosis	1.47e-05	0.000139	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—STAT3—multiple sclerosis	1.46e-05	0.000138	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MYC—multiple sclerosis	1.38e-05	0.00013	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFB1—multiple sclerosis	1.37e-05	0.00013	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MYC—multiple sclerosis	1.37e-05	0.000129	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFB1—multiple sclerosis	1.37e-05	0.000129	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MYC—multiple sclerosis	1.36e-05	0.000128	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFB1—multiple sclerosis	1.35e-05	0.000128	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MAPK1—multiple sclerosis	1.35e-05	0.000127	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MAPK1—multiple sclerosis	1.34e-05	0.000127	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MAPK1—multiple sclerosis	1.33e-05	0.000125	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOE—multiple sclerosis	1.29e-05	0.000122	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—POMC—multiple sclerosis	1.11e-05	0.000105	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6—multiple sclerosis	1.03e-05	9.76e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6—multiple sclerosis	1.03e-05	9.73e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6—multiple sclerosis	1.02e-05	9.64e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALB—multiple sclerosis	1.01e-05	9.55e-05	CbGpPWpGaD
